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Abstract
Background: Smoking is still prevalent among people with substance use disorders. The objective of this study
was to investigate the prevalence of smoking among patients in treatment for substance use disorders and to
analyze the effect of smoking both at baseline and follow-up on drop-out, mental health and quality of life.
Methods: One hundred and twenty-eight inpatients (26% female), mainly with alcohol use disorder, staying at
three different rehabilitation clinics in Eastern Norway, were interviewed at admission, and at 6 weeks and 6
months follow-up. The interview contained mental health-related problems, trauma, questions on alcohol and other
substances and quality of life. Non-parametric tests were used to test group differences and unadjusted and
adjusted linear regression to test the associations between smoking and the main outcome variables, while logistic
regression was used to test the association between smoking and drop-out.
Results: At admission, 75% were daily smokers. Compared to non-smokers at baseline, the smokers had higher
drop-out rates (37% vs. 13%), more mental distress, and lower quality of life from baseline up to 6 months follow-
up. Those quitting smoking while admitted improved in mental distress and quality of life at the same rate as non-
smokers. Alcohol-related factors did not differ between smokers and non-smokers.
Conclusions: Smoking was associated with mental distress, quality of life and treatment drop-out among patients
in primary alcohol use disorder treatment. The results indicate that smoking cessation should be recommended as
an integral part of alcohol use treatment both before and during inpatient treatment to reduce drop-out.
Keywords: Mental health problems, Alcohol use disorder, Smoking, Drop-out
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: lars.lien@sykehuset-innlandet.no
1Norwegian National Advisory Unit on Concurrent Substance Abuse and
Mental Health Disorders, Innlandet Hospital Trust, P.O. Box 104, 2381
Brumunddal, Norway
2Faculty of Social and Health Sciences, Inland Norway University of Applied
Sciences, Elverum, Norway
Full list of author information is available at the end of the article
Lien et al. BMC Psychiatry          (2021) 21:244 
https://doi.org/10.1186/s12888-021-03252-9
Background
Tobacco use is one of the leading preventable causes of
death in the world, killing up to half of users with a
particularly high toll on patients with mental health and
addiction problems [1]. The number of smokers in the
general population is rapidly decreasing. In 1973, 45% of
the Norwegian population were daily smokers, compared
to 26% in 2004 and 9% in 2020 [2]. These low figures
contrast with the prevalence of smoking among people
with addiction challenges, where studies from Australia
show that 61% of those with alcohol use disorder (AUD)
smoked compared with 22% of the general population in
2007 and that up to 77% of people in substance use de-
pendence (SUD) treatment were smokers [3]. In another
study, over a third of all smokers reported that they in-
creased their smoking during residential treatment [4].
There are several explanations for the high sustained
smoking rate among AUD patients. Studies have
identified a shared genetic predisposition to nicotine and
alcohol [5]. This results in both nicotine and alcohol
triggering the release of dopamine in the reward
pathway, possibly producing an increased effect [5, 6].
Furthermore, mental health problems are common in
AUD patients, and nicotine may often be used as a sort
of self-medication to relieve psychiatric symptoms [1].
Smoking also counters the sedative and cognitive effects
of alcohol and decreases the withdrawal symptoms [3].
Smoking may also act as a gateway drug to AUD and
other SUDs and be part of a drug-taking culture as alco-
hol increases the urge to smoke due to its disinhibiting
effects [7].
The effect of smoking on AUD treatment shows that
alcohol users who quit smoking in the first year after
treatment were two to three times more likely to stay
abstinent 9 years later [8]. Concurrent treatment for
tobacco and other drugs is recommended and a meta-
analysis of randomized controlled trials found that
patients who were treated concurrently were 25% more
likely to achieve long-term abstinence from alcohol than
those not receiving a smoking intervention [9]. Smoking
can trigger relapse to alcohol and similarly, relapse to
smoking is more likely when alcohol use is continued [10].
As early as 1976, Green and Levy [11] stated, “It is
practically impossible to cure an alcoholic (or problem
drinker) so long as he continues to smoke”. Although
this issue is still debatable, research has not provided an
answer as to the role of smoking in the pursuit of abstin-
ence from alcohol in patients with AUD [12]. It is im-
portant to continue research on smoking in patients
with AUD and other SUDs, as smoking is becoming a
more marginal phenomenon, with high use only in cer-
tain groups, e.g. persons with SUD. Many countries have
now barred smoking in public places including general
hospitals in an effort to curtail smoking, but addiction
and mental health treatment centers seem to remain an
exception to this trend [1]. Most previous studies point
to the fact that smoking and alcohol or other substance
addiction is a detrimental combination and that we need
more research on how smoking effects the AUD/SUD
treatment. The aim of this study among inpatients admit-
ted to substance abuse treatment is therefore to estimate
the prevalence of smoking and study baseline characteris-
tics and 6 months follow-up changes in mental health and
quality of life among smokers and non-smokers.
Materials and methods
Study design
This was an observational follow-up study using data
collected at baseline both as cross-sectional data and as
explanatory variables in the follow-up part of the study.
The baseline data were collected within the first week of
entry to the clinics, and the follow-up data at six-week
and six-month follow-up. During an interview conducted
by trained staff at baseline, we obtained information about
mental health, substance dependence, alcohol-related vari-
ables and trauma background. Mental distress and quality
of life measures were collected using self-report forms and
smoking status was obtained in an interview setting at all
three time points.
Study location
Data were collected from inpatients in three different re-
habilitation clinics in Eastern Norway. These clinics offer
treatment for patients with various substance use prob-
lems, mainly AUD, and the length of treatment stays
varies from three to 9 months.
Study participants and inclusion criteria
Altogether 366 patients were admitted to treatment in
the clinics during our inclusion period, of whom 238
(65%) were considered eligible for participation in the
study. Exclusion criteria were psychosis, cognitive im-
pairment or severe physical illness, as well as inability to
speak a Nordic language. The eligible patients were pro-
vided with information about the study and 128 (54%)
patients signed written informed consent.
Ethical considerations
The study was approved by the Norwegian Regional
Ethics Committee (ref. no. 2017/1314). We ensured that
all methods were used in accordance with relevant
guidelines and regulations.
Measures
Smoking When we collected data about smoking, the
participants were first asked: “Do you smoke cigarettes?”
Those who confirmed smoking were then asked “How
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often do you smoke?” with the response options of
‘Daily’ or ‘Occasionally’. In the following, smokers refers
to daily smokers, whereas non-smokers refers to those
who do not smoke cigarettes at all or only occasionally.
By comparing smoking status between time points, we
counted patients who quit smoking during the baseline/
six-week follow-up interval and during the six-week/six-
month follow-up interval, and similarly, those who
started smoking during these intervals.
Socio-demographic data Information about age and
sex was obtained during an interview performed at base-
line, whereas educational level and employment status
were reported in self-report forms collected at baseline.
Mental health outcome variables The Mini Inter-
national Neuropsychiatric Interview (M.I.N.I.) was used
to diagnose AUD and other SUD, in addition to PTSD,
current anxiety and lifetime depression [13]. Anxiety in-
cluded panic disorder, agoraphobia, social phobia, and
generalized anxiety disorder. The patients were asked
about their history of suicide attempts. Information
about traumatic experiences in childhood and adulthood
was collected by means of a five-item structured self-
report form. The three first questions targeted childhood
trauma and covered sexual abuse, physical abuse, and
other traumatic events with significant consequences,
while the two last questions covered sexual and physical
abuse and other traumatic events during adulthood. The
response alternatives for each item were 0) ‘None’ 1)
‘Yes, once’ and 2) ‘Yes, several times’, and dichotomous
variables (‘Yes’/‘No’) for childhood and adulthood trauma
were constructed.
Mental distress The Hopkins Symptom Checklist 10
question version (HSCL-10) is a widely used self-report
tool that covers common symptoms of anxiety and de-
pression experienced during the preceding week [14].
Each item has four ordinal responses, ranging from 1)
‘Not at all’ to 4) ‘Extremely’. The average score for each
individual was calculated yielding a score between 1 and
4, where a higher score corresponded to more mental
distress.
Quality of life We used a five-item Quality of life (QoL-
5) instrument to measure patient satisfaction with life in
general [15]. This tool targets self-perceived quality of
mental and physical health, and relationship to oneself
and to significant others. There are five ordinal response
alternatives ranging from 1) ‘Very good’ to 5) ‘Very
poor’. The raw scores are transposed and inverted into a
total score between 10 and 90, where a higher score in-
dicates better life quality.
Treatment drop-out Treatment drop-out was defined
as discontinuation of treatment stay by leaving the clinic
before the planned completion. Planned duration of
treatment stay varied between patients and clinics from
three to 9 months. The final follow-up of the study was
at 6 months and patients still in treatment at this time
point were regarded as non-drop-outs. Three patients
discontinued treatment for other reasons and were not
included in the analysis of the drop-out rate.
Alcohol-related measures The Alcohol Use Disorders
Identification test (AUDIT) was used to measure harm-
ful drinking of alcohol. This is a 10-question instrument
with responses dealing with use of alcohol during the
preceding year [16]. All items have responses ranging
from 0 to 4, which are added up to a total score between
0 and 40, where a higher score indicates more problem-
atic alcohol use. In addition to the AUDIT, we asked the
participants about their age at first drink and whether
their parents had problems with alcohol.
Physical activity Physical activity was measured with
the International Physical Activity Questionnaire short
version (IPAQ-S) [17, 18]. Patients reported all activities
during leisure time, work, domestic activities, and trans-
port during the preceding week. The number of days
and minutes spent doing vigorous exercise, moderate
exercise, walking or sitting was specifically reported in
seven questionnaire items. Based on this information the
patients were categorized into three levels of physical ac-
tivity: low, moderate or high [19]. For the purpose of this
study we dichotomized the variable into low vs. moder-
ate/high.
The adult ADHD self-report questionnaire To
measure current ADHD (attention deficit hyperactivity
disorder) symptoms, we used the six-item version of the
Adult ADHD Self-Report Scale (ASRS), which has dem-
onstrated good specificity and sensitivity [20]. The six
items target inattentiveness and hyperactivity symptoms
and there are five ordinal response alternatives ranging
from 0) ‘Never’ to 4) ‘Very often’. We calculated the total
score of the six items, using a cut-off point of ≥14 [21].
Statistical analyses
Statistical analyses were performed using STATA ver-
sion 15. At baseline we had data for 128 individuals for
smoking, socio-demographics and most mental health
variables. Thirty-one persons did not return their ques-
tionnaire (including HSCL-10, QoL, ASRS and AUDIT)
and are missing in the analyses where these forms were
used. The means were imputed for two persons for
the HSCL-10 and one person for the AUDIT who
had < 20% missing items on these measures.
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We used medians and inter-quartile percentiles to de-
scribe the samples and non-parametric tests to test
group differences. Unadjusted and adjusted linear re-
gression models were used to test the associations be-
tween smoking and mental distress and between
smoking and quality of life, while logistic regression was
employed to test the association between smoking and
treatment drop-out. The model is only adjusted for age
and sex due to small sample size and low power (66 par-
ticipants at 6 months).
Results
Of the patients who declined participation, 76 were men
(69%; mean age 48.7, standard deviation (SD) 11.6) and
34 were women (31%; mean age 46.3, SD 11.5). There
were no significant differences between included and ex-
cluded individuals regarding sex or age.
Table 1 shows the differences in sociodemographics,
mental health and alcohol- related variables at baseline
between smokers and non-smokers. There were no sig-
nificant differences in sex or age between the groups.
Non-smokers had significantly higher educational levels
in terms of both secondary education and college/uni-
versity (p = 0.002 and p < 0.001, respectively).
Non-smokers were more physically active than
smokers (p = 0.037). Non-smokers had had fewer suicide
attempts (p = 0.018) than smokers, and there was a trend
towards fewer patients with an anxiety diagnosis among
non-smokers (Table 2). For the other mental health-
related variables, there were no differences between
smokers and non-smokers, including childhood and
adulthood trauma and PTSD, lifetime depression and
ASRS score above cut-off indicating ADHD diagnosis.
There was a difference in age at first drink, where
Table 1 Demographics and health variables stratified by smoking habits among the patients included (N = 128) at baseline
Non-smoker Smoker p
n = 32 n = 96
Demographics
Sex (female) n (%) 11 (34) 23 (24) 0,248e
Age (years) Median (IQRd) 49 (37–58) 53 (44–57) 0.411f
13 years of education n (%) 23 (96) 44 (63) 0.002e
16 years of education n (%) 16 (62) 9 (13) < 0.001e
In paid work n (%) 6 (23) 12 (16) 0.451e
> low physical activity levela n (%) 14 (61) 24 (36) 0.041e
Mental health background
ASRS score > cutoff n (%) 11 (44) 33 (46) 0.831e
Anxietyb n (%) 15 (48) 64 (67) 0.068e
Depression, lifetime n (%) 24 (77) 71 (74) 0.700e
Childhood trauma n (%) 18 (72) 52 (72) 0.983e
Adulthood trauma n (%) 17 (68) 47 (65) 0.805e
PTSD n (%) 4 (13) 20 (21) 0.296e
Suicide attempt n (%) 4 (13) 33 (34) 0.018e
Alcohol-related variablesc
Parent with alcohol problems n (%) 16 (57) 45 (53) 0.699e
Age first drink (years) Median (IQRd) 16 (15–17) 15 (13–16) 0.028f
AUDIT score Median (IQRd) 28 (26–34) 30 (24–34) 0.874f
Substance dependence
Alcohol n (%) 28 (88) 85 (89) 0.874e
Other substance n (%) 9 (28) 28 (29) 0.910e
Alcohol and other substance n (%) 5 (16) 17 (18) 0.787e
Treatment clinic
Clinic 1 n (%) 21 (66) 40 (42) 0.058
Clinic 2 n (%) 6 (19) 26 (27)
Clinic 3 n (%) 5 (16) 30 (31)
aInternational physical activity questionnaire short version (IPAQ-S), low vs. moderate/high level. bAnxiety: panic disorder, agoraphobia, social phobia or
generalized anxiety disorder. cAlcohol-dependent patients only (n = 113). dInter-quartile percentiles (25 and 75%). eChi-square tests. fMann-Whitney U tests
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smokers had an earlier debut than non-smokers (15 ver-
sus 16 years of age, p = 0.028). There were no differences
in AUDIT scores, whether they had a parent with prob-
lem drinking or other substance dependencies.
Study participants were staying at three different treat-
ment locations. The average age ranged from 48.3 to
51.8 years in the three clinics. There were 44% females
in one of the clinics, 19% in the other and the third was
restricted to men only. The clinic with most women had
the highest number of non-smokers (Table 1).
There were 96 (75%) daily smokers and 32 (25%) non-
smokers at baseline (Table 2). One patient started
smoking, and nine patients quit smoking during the
study period of 6 months, six before 6 weeks and three
after 6 weeks. Three of the six that quit early dropped
out before 6 months so at 6 months there were still six
quitters.
Table 3 shows baseline, 6 weeks and 6 months follow-
up of mental distress, quality of life and drop-out from
treatment. Non-smokers had fewer symptoms of mental
distress (HSCL-10) at baseline than smokers (1.8 versus
2.2, p = 0.044). In addition, at 6 weeks and 6 months
follow-ups non-smokers tended to have lower distress
scores than smokers, but the differences were not statis-
tically significant. There were similar findings for life
quality with better QoL scores at baseline, though not
statistically significant (p = 0.062), but at 6 months QoL
scores in favor of non-smokers were significantly higher
(70 versus 63, p = 0.037). The numbers of patients who
dropped out of treatment after 6 months was four (13%)
among the non-smokers and 35 (37%) among the
smokers (p = 0.015), whereas at 6 weeks there was no
difference between the groups. Figure 1 also shows this,
but includes only those 45 participants with complete
data for all three measurement points. The main differ-
ence in the figure is that smokers show a significant
drop in HSCL score compared to non-smokers at 6
weeks.
There were no significant differences in baseline
characteristics between patients that quit smoking
(n = 9) and those who continued smoking during the
treatment period, either in demographics, psychiatric
conditions, alcohol-related measures or mental dis-
tress and quality of life (not shown in table). Those
who quit smoking reported improved quality of life
during the stay, matching the levels of non-smokers
at 6 weeks and 6 months follow-up (Median 57
(interquartile percentiles 48–67) at baseline, 67 (57–
79) at 6 weeks and 70 (63–70) at 6 months). There
was a corresponding decrease in symptoms of mental
distress (1.9 (1.2–2.1) at baseline, 1.6 (1.1–2.6) at 6
weeks and 1.1 (1.0–1.9) at 6 months). Due to the
small numbers involved, we were unable to make
comparisons with the rest of the sample.
Table 4 shows bivariate and adjusted linear regression
models of the effect of daily smoking on mental distress
and quality of life at baseline and bivariate and adjusted
logistic regression models of the effect of daily smoking
on treatment drop-out status at 6 months follow-up.
Table 3 Levels of mental distress and life quality scores at baseline and follow-ups, and drop-out rate at 6 month follow-up
Non-smoker Smoker p-value
HSCL-10
Baseline (n = 97) Median (IQRa) 1.8 (1.4–2.2) 2.1 (1.5–2.6) 0.044b
6 weeks (n = 73) Median (IQRa) 1.6 (1.3–2.3) 1.9 (1.4–2.3) 0.680b
6 months (n = 45) Median (IQRa) 1.6 (1.4–1.7) 1.8 (1.5–2.1) 0.253b
QoL
Baseline (n = 97) Median (IQRa) 63 (53–70) 53 (43–63) 0.062b
6 weeks (n = 73) Median (IQRa) 63 (50–70) 63 (53–70) 0.802b
6 months (n = 45) Median (IQRa) 70 (67–77) 63 (53–70) 0.037b
Treatment drop-out
6 weeks (n = 125) n (%) 3 (10) 10 (11) 0.934c
6 months (n = 125) n (%) 4 (13) 35 (37) 0.015c
HSCL-10 Hopkins Symptoms Check-list 10, QoL Quality of Life questionnaire
aInter-quartile percentiles (25 and 75%). bMann-Whitney U tests. cChi-square test statistics
Table 2 Smoking habits at baseline, and at six weeks and six
months follow-ups
Baseline Six weeks Six months
n = 128 n = 100 n = 66
Non-smoker n (%) 32 (25)
Continuing non-smoker n (%) 23 (23) 18 (27)
Quit smoking n (%) 6 (6) 6 (9)
Smoker n (%) 96 (75)
Continuing smoker n (%) 70 (70) 41 (62)
Started smoking n (%) 1 (1) 1 (2)
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Smoking was associated with mental distress with higher
baseline HSCL-10 scores for smokers after adjusting for
age and sex (beta 0.48, p = 0.002). There was a significant
adjusted association between smoking and quality of life
(beta -6.91, p = 0.050). Smoking was associated with
drop-out status at 6 months follow-up after adjustment
(OR 3.76, p = 0.023).
Discussion
The main finding from this study of SUD (mainly AUD)
patients receiving inpatient treatment were that com-
pared to non-smokers, smokers had higher drop-out
rates, significantly more mental distress at baseline, and
significantly lower quality of life at 6 months follow-up.
The finding on drop-out rate is in line with a German
Fig. 1 Development of mental distress and life quality during treatment period. Notes: Mental distress (HSCL-10) score (upper panel) and quality
of life (QoL) score (lower panel) for smokers vs. non-smokers at baseline, 6 weeks and 6 months follow-ups. Medians and 25% or 75% percentiles
are presented. Friedman tests were used to test differences across time. Complete cases are included (n = 45)
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study showing that smoking status at the beginning of
alcohol abstinence among alcohol-dependent patients
was associated with drinking outcomes where smokers
had a significantly higher risk of relapse to alcohol
drinking than non-smokers within the first 12 months
after detoxification [12]. This finding was corroborated
by Weinberger et al. [10], who found the same pattern
in a national epidemiological study in the USA among
readmitted patients with AUD. They showed that cigarette
smoking at baseline was significantly associated with a
greater likelihood of alcohol abuse and dependence at 3
years follow-up compared to non-smokers. The associa-
tions remained significant after adjusting for demograph-
ics, psychiatric disorders, other substance use disorders,
AUD severity, and criteria for nicotine dependence.
Drop-out rate is a major issue in addiction therapy. In
our sample, 10% dropped out of treatment before 6
weeks and 31% before 6 months. A number of studies
have investigated possible factors contributing to drop-
out. In a comprehensive meta-analysis, Brorson et al.
found that cognitive deficits, low treatment alliance, per-
sonality disorder, and younger age were predictive of
drop-out [22]. In a more recent meta-analysis, Lappan
et al. found that drop-out rates also increased with a
higher number of cigarettes per day at intake [23]. This
is not directly comparable with our study as we have in-
vestigated the effect of abstinence from tobacco.
Another finding from this study is that there is still a
very high proportion of current daily smokers among
inpatients for alcohol dependence treatment compared
to the rest of the population. Our finding of 75%
smokers among patients in treatment for alcohol or
other substance dependence is in line with a study from
Australia reporting 61% smokers among AUD patients
in the general population and 77% smokers among
AUD patients in treatment in 2007 [3]. It also agrees
with a more recent study from Germany where 75% of
patients in alcohol detox treatment were current
smokers at intake [12]. In an epidemiological study by
Weinberger et al. comparing smoking cessation rates in
the past 12 years, the authors found that the cessation
rate for persons with AUD was approximately half that
of persons without AUD [24].
Smokers had significantly poorer mental distress
scores at baseline, but improved their scores during the
six-month period, probably due to the general treatment
effect. The poorer mental health status of the smokers
was confirmed by their higher incidence of suicide at-
tempts. This has been confirmed in a study by Jung
et al., showing higher suicide rates among those addicted
to both nicotine and alcohol compared with addiction to
only one substance [25]. Both smokers and non-smokers
improved their QoL scores during the treatment period,
but smokers had lower QoL scores at all times and sig-
nificantly lower than non-smokers at 6 months. Several
studies have shown an association between lifestyle fac-
tors and life quality [26].
There are also other possible reasons why the quality
of life and mental health status of smokers are lower
than those of non-smokers. Persons with SUDs are more
likely to suffer from financial and social hardship and
with increasing taxation, the use of cigarettes may
consume a substantial part of their monthly expenses,
making it increasingly difficult to afford food and
shelter. In addition to severe financial hardship, there
is societal stigma associated with smoking, leading to
challenges in integration into communities and work-
places that no longer tolerate smoking. This comes in
addition to the stigma connected to mental health
and addiction problems [27].
There seemed to be no difference in levels of harmful
drinking among smokers and non-smokers. A kind of
threshold effect could explain this lack of difference, lev-
elling off differences at start of treatment as severity of
alcohol addiction is the main criteria for admission. The
difference is, however, visible in age of onset of drinking
as the average age was 16 for non-smokers and 15 for
smokers. Smoking is known to be a risk factor for early
start and heavy drinking [28]. Another interesting dif-
ference between smokers and non-smokers was that
non-smokers were more physically active at baseline.
It is difficult to know whether physical activity helped
participants quit smoking or whether smoking re-
duced physical activity.
What conclusions can we draw in terms of treatment?
From our findings and the possible underlying mechanisms
Table 4 Bivariate and adjusted linear regression models of effect of daily smoking on HSCL-10 and QoL at baseline and bivariate
and adjusted logistic regression model of effect of daily smoking on treatment drop-out during 6 months
HSCL-10 QoL Drop-out
Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted
Reference category β p β p β p β p OR p OR p
Sex Male 0.63 < 0.001 0.70 < 0.001 −3.34 0.350 −4.47 0.216 0.89 0.792 1.05 0.922
Age Continous variable −0.01 0.247 −0.01 0.202 0.08 0.587 0.09 0.531 1.01 0.414 1.01 0.480
Smoking Non-smoker 0.34 0.035 0.48 0.002 −6.01 0.083 −6.91 0.050 3.79 0.021 3.76 0.023
HSCL-10 Hopkins’ Symptoms Check-list 10, QoL Quality of Life questionnaire. Adjusted models includes all three covariates
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described above, alcohol and tobacco addiction should be
treated in an integrated manner. In a recent meta-analysis,
smoking cessation treatment and smoking abstinence in-
creased the chance of abstinence from alcohol and/or illicit
drugs. All studies were rated as being of strong or moderate
quality by the investigators [29]. According to several alco-
hol treatment guidelines, including those in Norway, smok-
ing cessation treatment should be offered to all people with
SUD and the recommendations are similar to those for
smokers without SUD [30]. One important message is that
SUD patients are also able to quit smoking. Although the
cessation rate is lower than in the general population, it is
still at around 20% [31].
There are some limitations to this study. The current
work is based on a mixed sample of which about nine in
ten have AUD and the others have other SUDs. How-
ever, these were distributed evenly across smoking
groups. In addition to the patients who completed their
treatment stay before 6 months, those who were still in
treatment at 6 months follow-up were regarded as non-
drop-outs, raising the possibility of miscategorizing some
patients. A larger sample size would have made it pos-
sible to better characterize patients who succeeded in
quitting smoking and reduced the risk of false negatives.
Conclusion
Smoking seems to be an important factor in the treat-
ment of substance use disorders as smoking at baseline
is associated with mental distress, quality of life and
drop-out rate. The results indicate that smoking cessa-
tion may be recommended as an integral part of alcohol
abuse treatment both before and during inpatient treat-
ment to reduce drop-out and even improve the out-
comes of mental health and quality of life.
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